Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor.
Published in | Cancer Research Journal (Volume 11, Issue 3) |
DOI | 10.11648/j.crj.20231103.14 |
Page(s) | 105-111 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Ovarian Cancer, Treatment, Breast Cancer, Guinean Oncological Environment
[1] | Institut Curie. Breast cancer. [Accessed March 11, 2021]. Available at: https://curie.fr/page/le-cancer-du-sein |
[2] | Lokossou A. Ovarian cancer: epidemiology, natural history, clinical study. Cours université d'Abomey- Calavi Bénin: 82p. [Accessed 04 February 2021]. Available from http://umvf.cerimes.fr/media/ressMereEnfant/CAN/Libreville2012/videocours/3-02-Libreville2012-Lokossou_html5/media/pdf/3.02_Lokossou.pdf |
[3] | Schonfeld SJ, Berrington de Gonzalez A, Visvanathan K, et al. Declining second primary ovarian cancer after first primary breast cancer. J Clin Oncol. 2013; 31 (6): 738-43.a. |
[4] | Zoukar O, Haddad A, Daldoul A et al. Genital metastases from breast cancer: study of 3 cases and literature review. Pan Afr Med J. 2018; 30 (7): 7. |
[5] | Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors. [Accessed 06 February 2021]. Available at: https://seer.cancer.gov/archive/publications/mpmono/ |
[6] | Crouet H, Lesur A, Blanc-Fournier C et al. Ovarian, peritoneal and retroperitoneal metastases in breast cancer. 29th meeting of the French Society of Senology and Breast Pathology (SFSPM). Advanced breast cancer. Avignon, France. 2007. 239p. |
[7] | Wang J., Tian W., Zhou Y. et al. Ovarian metastasis from breast cancer in three Chinese females: Three case reports. China: Wolters Kluwer Health, Inc; 2019; 98 (17); e15395. |
[8] | Dubois N., Willems T., Myant N. Métastase ovarienne du cancer du sein: à propos d'un cas. Rôle de la chirurgie cytoréductrice. Eur J Obst Gyn Reprod Biol; 2009; 38 (3): 242-245. |
[9] | Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin. 2009 59 (4): 225-49. |
[10] | Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011; 284 (5): 1283-8. |
[11] | Chabbert-Buffet N, Seroussi B, Chopier J et al. Modalités de fonctionnement d'un centre de prise en charge des femmes à haut risque de cancer du sein et de l'ovaire: l'expérience française de l'hôpital Tenon. Gynecol Obstet Fertil. 2010; 38 (3): 183-92. |
[12] | Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre-and perioperative characteristics. Gynecol Oncol. 2006; 101 (1): 97-101. |
[13] | Le Thai N, Lasry S, Brunet M et al. Cancer de l'ovaire après cancer du sein. 45 cars. J Gynecol Obstet Biol Reprod (Paris). 1991; 20 (8): 1043-8. |
[14] | Gagnon Y, Têtu B. Métastases ovariennes d'un carcinome mammaire. Etude clinicopathologique de 59 cas. Cancer. 1989; 64 (4): 892-8. |
[15] | Le Bouëdec G, de Latour M, Levrel O, Dauplat J. Tumeurs de krükenberg d'origine mammaire. 10 observations. Presse Med. 1997 Mar 29; 26 (10): 454-7. |
[16] | Perrotin F, Marret H, Bouquin R et al. Incidence, diagnostic et pronostic des métastases ovariennes dans le cancer du sein. Gynecol Obstet Fertil. 2001; 29 (4): 308-15. |
[17] | Société canadienne du cancer. Facteurs de risque du cancer du sein. [Consulté le 03 mai 2021]. Disponible sur: https://www.cancer.ca:443/fr-ca/cancer-information/cancertype/breast/risks/?region=qc. |
[18] | Rabban JT, Barnes M, Chen L-M et al. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009; 33 (8): 1125-36. |
[19] | Ayhan A, Guvenal T, Salman MC et al. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol. 2005; 98 (2): 235-41. |
[20] | Abu-Rustum NR, Aghajanian CA, Venkatraman ES et al. Metastatic breast carcinoma to the abdomen and pelvis. Gynecol Oncol. 1997; 66 (1): 41-4. |
[21] | Han X, Jemal A. Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U. S. Am J Prev Med. 2017; 53 (4): 504-7. |
[22] | Schneider J, Lahl J, Kramer W. Risque de cancer du sein à long terme après stimulation ovarienne chez les jeunes donneuses d'ovules: un appel au suivi, à la recherche et au consentement éclairé. Reprod Biomed Online. 2017; 34 (5): 480-5. |
APA Style
Bah Malick, Toure Alhassane Ismael, Keita Mamady, Cisse Kalil, Souare Mamadou Bobo, et al. (2023). Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Research Journal, 11(3), 105-111. https://doi.org/10.11648/j.crj.20231103.14
ACS Style
Bah Malick; Toure Alhassane Ismael; Keita Mamady; Cisse Kalil; Souare Mamadou Bobo, et al. Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Res. J. 2023, 11(3), 105-111. doi: 10.11648/j.crj.20231103.14
AMA Style
Bah Malick, Toure Alhassane Ismael, Keita Mamady, Cisse Kalil, Souare Mamadou Bobo, et al. Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Res J. 2023;11(3):105-111. doi: 10.11648/j.crj.20231103.14
@article{10.11648/j.crj.20231103.14, author = {Bah Malick and Toure Alhassane Ismael and Keita Mamady and Cisse Kalil and Souare Mamadou Bobo and Conde Ibrahima Kalil and Cisse Mohamed Falilou and Traore Bangaly}, title = {Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting}, journal = {Cancer Research Journal}, volume = {11}, number = {3}, pages = {105-111}, doi = {10.11648/j.crj.20231103.14}, url = {https://doi.org/10.11648/j.crj.20231103.14}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20231103.14}, abstract = {Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor.}, year = {2023} }
TY - JOUR T1 - Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting AU - Bah Malick AU - Toure Alhassane Ismael AU - Keita Mamady AU - Cisse Kalil AU - Souare Mamadou Bobo AU - Conde Ibrahima Kalil AU - Cisse Mohamed Falilou AU - Traore Bangaly Y1 - 2023/09/14 PY - 2023 N1 - https://doi.org/10.11648/j.crj.20231103.14 DO - 10.11648/j.crj.20231103.14 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 105 EP - 111 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20231103.14 AB - Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor. VL - 11 IS - 3 ER -